Berenberg Bank Analysts Give Fresenius Medical Care AG & Co. KGaA (ETR:FME) a €89.95 Price Target
Berenberg Bank set a €89.95 ($104.59) price target on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a research report released on Thursday, Borsen Zeitung reports. The firm currently has a buy rating on the stock.
Several other research firms have also recently commented on FME. Morgan Stanley restated an overweight rating and set a C$125.00 price target on shares of Intact Financial in a research note on Wednesday, May 15th. Barclays restated a hold rating and set a $14.00 price target on shares of MACOM Technology Solutions in a research note on Thursday, June 20th. Independent Research set a €74.00 ($86.05) price target on Fresenius Medical Care AG & Co. KGaA and gave the stock a neutral rating in a research note on Monday, June 17th. HSBC set a €101.00 ($117.44) price target on Grenke and gave the stock a buy rating in a research note on Thursday, April 25th. Finally, Goldman Sachs Group set a $13.00 price target on Ford Motor and gave the stock a buy rating in a research note on Thursday, June 13th. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of €82.57 ($96.01).
Shares of ETR FME opened at €69.70 ($81.05) on Thursday. The company has a debt-to-equity ratio of 100.05, a quick ratio of 0.67 and a current ratio of 1.02. Fresenius Medical Care AG & Co. KGaA has a twelve month low of €55.44 ($64.47) and a twelve month high of €91.74 ($106.67). The company has a 50 day moving average price of €68.10. The stock has a market capitalization of $21.28 billion and a PE ratio of 10.85.
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Recommended Story: Why do companies issue stock splits?
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.